Veeva Systems (VEEV)
(Delayed Data from NYSE)
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) see strong testing volumes from new products.
Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff
by Zacks Equity Research
Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.
Myriad Genetics Announces Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.
Illumina (ILMN) Takes Part in NIH Program With Genotype Launch
by Zacks Equity Research
The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.
Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
QIAGEN Partners With Novartis to Expand CDx Tests Suite
by Zacks Equity Research
QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.
Time to Focus on Veeva Systems (VEEV) for Strong Earnings Growth Potential
by Zacks Equity Research
Veeva Systems (VEEV) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Quest Diagnostics Rides on Product Launches, Strategic Deals
by Zacks Equity Research
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
by Zacks Equity Research
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Veeva Systems Announces New DAM Solution for Life Sciences
by Zacks Equity Research
Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed's (CHE) subsidiaries continue to register strong sales.
ResMed to Buy Propeller Health, Widens Respiratory Care Suite
by Zacks Equity Research
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.
Genomic Health (GHDX), BioCartis Extend Deal to Urology
by Zacks Equity Research
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
Here's Why You Should Invest in Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
Zimmer Biomet Rides on New Operational Plan Amid Several Woes
by Zacks Equity Research
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance
by Zacks Equity Research
Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
by Zacks Equity Research
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) continues to witness strong conversion wins for new XT series.
Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth
by Zacks Equity Research
Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.
CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing
by Zacks Equity Research
The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.
QIAGEN's New Offerings to Broaden Hematology Testing Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to progress with test menu expansion.
Here's Why You Should Invest in Surmodics (SRDX) Right Now
by Zacks Equity Research
A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.
BD Brings HealthSight Diversion App to Combat Opioid Crisis
by Zacks Equity Research
BD's (BDX) latest development is likely to boost the company's Medication Management unit.